Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

• Status: Not yet recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: All

Summary

•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tanta University
• Treatments: Empagliflozin

Criteria

Inclusion Criteria:

•Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.

Exclusion Criteria:

• Other inflammatory bowel diseases (CD).

• History of serious hypersensitivity to empagliflozin or any component of the formulation.

• Patients on dialysis.

• Severe renal impairment (eGFR <20 ml/minute/1.73m2) .

• Chronic urinary tract infection.

• Chronic genital infection.